The DEA is proposing to place concentrated synthetic 7-hydroxymitragynine (7-OH) products — a potent kratom-derived compound — under Schedule I of the Controlled Substances Act. The move targets products with elevated 7-OH concentrations widely sold in gas stations and online, while exempting natural leaf kratom. Addiction specialists are calling it an encouraging but incomplete step.
The Drug Enforcement Administration (DEA) has proposed placing concentrated synthetic 7-hydroxymitragynine (7-OH) products under Schedule I of the Controlled Substances Act — the same category as heroin and LSD. The proposal targets products containing more than 0.050% 7-OH by weight or more than 1.0 mg per article, as well as three synthetic 7-OH derivatives. Natural leaf kratom with trace levels of 7-OH would be exempt.
7-OH is a potent opioid receptor agonist found in trace amounts in the kratom plant, but concentrated synthetic versions are 30–40 times more potent and are widely sold as gummies, tablets, and liquid shots in convenience stores and online. The proposal follows a 2025 FDA recommendation to schedule 7-OH and warning letters sent to seven companies marketing these products.
Key Takeaways:
Why it matters: With high-potency 7-OH products freely available in everyday retail settings, this DEA action could meaningfully reduce public exposure to a substance with serious addiction and overdose potential — but enforcement and monitoring remain significant challenges.
